Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions containing the compounds of formula (I).

Abstract: A compound of the formula wherein D, E, F, G, L, T, W, X, Y, Z, U, A, R1, R2, R3, R4, R5, R6 R7 are as defined in the specification, pharmaceutical compositions thereof, and methods of use to treat diseases and as D3 receptor modulators.

Abstract: This invention relates to novel acylamino cyclopropane derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as modulators of dopamine D3 receptors and for the treatment of anxiety, psychosis, substance abuse, Parkinson's disease, sexual dysfunction, and other central nervous system disorders.

Abstract: This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1 through R6 are as defined in the specification These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.

Abstract: This invention relates to novel acylamino cyclopropane derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as modulators of dopamine D3 receptors and for the treatment of anxiety, psychosis, substance abuse, Parkinson's disease, sexual dysfunction, and other central nervous system disorders.

Abstract: The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor and an acetylcholine esterase inhibitor.

Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:

Abstract: Pharmaceutically active benzimidazole derivatives are disclosed comprising compounds of the formula: ##STR1## particularly wherein X is nitrogen, R.sup.1 is phenyl or heteroaryl, and one of R.sup.2 or R.sup.3 is hydroxy.

Abstract: This invention relates to novel, pharmaceutically active benzimidazolone derivatives of the formula ##STR1## wherein the dashed line, R.sup.0 through R.sup.6 and X.sup.1 through X.sup.3 are defined as in the specification. These compounds exhibit central dopaminergic activity and are u in the treatment of CNS disorders.

Abstract: Substituted pydrido?1,2-a!pyrazines of general formula I wherein Ar and Ar.sup.1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO.sub.2, C.dbd.O, CHOH, or --(CR.sup.3 R.sup.4) and n is 0-2 as well as precursors thereto are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment of disorders of the dopamine system.

Abstract: 2,6-Diaminopurines, 3,5-diamino-6,7,8,9-tetrahydrobenzo[b]thiophene[2,3-d]pyrimidines and 2,4-diaminothieno[3,2-d]pyrimidines useful as inhibitors of P-glycoproteins and potentiators of chemotherapeutic agents.

Abstract: 2,4,6-Triaminotriazine derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.

Abstract: 2,4-diaminopyrimidine derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.

Abstract: 2,4-Diaminoquinazoline derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.

Abstract: Acyl derivatives of 2-aminobenzothiazole and alkylated analogs thereof as antitumor agents.

Abstract: Compounds of the formula ##STR1## where HET is a heterocyclic group, n is an integer of 0 to 2 and R.sup.1 is hydrogen or lower alkyl are protease inhibitors useful as anti-plasmin and antithrombin agents.

Abstract: Compounds of the formula ##STR1## where Het is a heterocyclic group, n is an integer of 0 to 2 and R.sup.1 is hydrogen or lower alkyl are protease inhibitors useful as anti-plasmin and anti-thrombin agents.

Abstract: A digitally trunked radio repeater system provides substantial improvements in timeliness of channel acquisition and channel drop, and in reliability of critical control signalling. The system uses a much higher digital signalling rate than is typically found in prior art systems, and uses a control channel to convey digital channel request and assignment messages between the central site and mobile transceivers. The mobile radio transceivers transmit channel requests on the control channel (if no response is received, the mobile retries during a retry time window which increases in duration in dependence on the number of retries). The mobile transceiver switches to a working channel in response to an assignement message received on the control channel. Subaudible digital signals transmitted on the control channel and on active working channels allow late entry, shifting to higher priority calls, and other advanced functions.